remote electrical neuromodulation News
-
Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today that a new peer-reviewed study published in Pain and Therapy demonstrates the efficacy of Nerivio® in treating menstrual migraine. Menstrual migraine, a sub-type of migraine, is often more painful, more disabling and of longer duration compared to ...
-
Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a study in Pain Medicine that compared adolescent response to migraine medications to their response to Remote Electrical Neuromodulation (REN) administered by Nerivio®. The study found statistically significant differences in ...
-
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. "We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital ...
-
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning a new HCPCS Level II code K1023 "Distal Transcutaneous Electrical Nerve Stimulator, Stimulates ...
-
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio in Patients with Chronic Migraine
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute ...
-
Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the appointment of Scott Serota to its Board of Directors. "Over the course of the past few decades, which I have dedicated to enabling patients of various medical conditions access to new treatments, I developed passion for supporting the advancement ...
-
FDA Approves Theranica`s Nerivio® for Acute Treatment of Migraine in Adolescents
Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you